Infrastructure, capabilities, and capacities required for clinical trials design and delivery: A rapid scoping review of recommendations and regulations.
Laura Merson, Karolina Witt, Arishay Hussaini, Ayesha Siddiqui, Eli Harriss, Steve Webb, Patricia Njuguna, Divya K Shah, An-Wen Chan, Robert Terry, Nandi Siegfried, Jeni Stolow, Emmanuelle Denis, Madiha Hashmi
{"title":"Infrastructure, capabilities, and capacities required for clinical trials design and delivery: A rapid scoping review of recommendations and regulations.","authors":"Laura Merson, Karolina Witt, Arishay Hussaini, Ayesha Siddiqui, Eli Harriss, Steve Webb, Patricia Njuguna, Divya K Shah, An-Wen Chan, Robert Terry, Nandi Siegfried, Jeni Stolow, Emmanuelle Denis, Madiha Hashmi","doi":"10.12688/wellcomeopenres.23135.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Synthesise the published literature and national regulations on infrastructure, capabilities and capacities required to manage and quality assure clinical research.</p><p><strong>Introduction: </strong>The World Health Assembly (WHA) resolution 75.8 (2022) called \"for a strengthened global architecture for coordinated and high-quality clinical trials\". For this remit, infrastructure, capabilities, and capacities needed to design and deliver high-quality clinical trials must be understood and advanced. This rapid scoping review aims to identify the breadth of requirements and recommendations for effective management of clinical trials in regulations, national legislation and the published literature. The findings will be summarised into themes. It will inform a framework for the assessment and development of units undertaking observational studies and interventional clinical trials.</p><p><strong>Inclusion criteria: </strong>Peer-reviewed literature, grey literature, and national legislation that recommends infrastructure, capabilities, and/or capacities needed to manage and quality assure clinical trials. Publications authored by those who design, manage, fund, sponsor, regulate or oversee clinical trials.</p><p><strong>Methods: </strong>Peer-reviewed and grey literature will be identified through Medline, Embase, PsycINFO, and Global Health via Ovid; SCOPUS; the Web of Science Core Collection; and the WHO Global Index Medicus using specific field codes to increase the specificity of the search strings. No date, language, or geographic limits will be applied. Deduplicated titles and abstracts will be screened by two blinded reviewers with discrepancies resolved by a third reviewer. Grey literature may be identified through the peer reviewed literature, supplemented with structured searches of Google and DynaMed. National regulations will be sourced online and from available summaries. Full text literature and regulations will be screened by a single reviewer, with proportionate verification by a second reviewer. Data will be extracted and coded for patterns in NVivo software. All items and codes will be summarised using a thematic framework analysis and identify core constructs within each theme.</p>","PeriodicalId":23677,"journal":{"name":"Wellcome Open Research","volume":"9 ","pages":"729"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923532/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wellcome Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/wellcomeopenres.23135.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Synthesise the published literature and national regulations on infrastructure, capabilities and capacities required to manage and quality assure clinical research.
Introduction: The World Health Assembly (WHA) resolution 75.8 (2022) called "for a strengthened global architecture for coordinated and high-quality clinical trials". For this remit, infrastructure, capabilities, and capacities needed to design and deliver high-quality clinical trials must be understood and advanced. This rapid scoping review aims to identify the breadth of requirements and recommendations for effective management of clinical trials in regulations, national legislation and the published literature. The findings will be summarised into themes. It will inform a framework for the assessment and development of units undertaking observational studies and interventional clinical trials.
Inclusion criteria: Peer-reviewed literature, grey literature, and national legislation that recommends infrastructure, capabilities, and/or capacities needed to manage and quality assure clinical trials. Publications authored by those who design, manage, fund, sponsor, regulate or oversee clinical trials.
Methods: Peer-reviewed and grey literature will be identified through Medline, Embase, PsycINFO, and Global Health via Ovid; SCOPUS; the Web of Science Core Collection; and the WHO Global Index Medicus using specific field codes to increase the specificity of the search strings. No date, language, or geographic limits will be applied. Deduplicated titles and abstracts will be screened by two blinded reviewers with discrepancies resolved by a third reviewer. Grey literature may be identified through the peer reviewed literature, supplemented with structured searches of Google and DynaMed. National regulations will be sourced online and from available summaries. Full text literature and regulations will be screened by a single reviewer, with proportionate verification by a second reviewer. Data will be extracted and coded for patterns in NVivo software. All items and codes will be summarised using a thematic framework analysis and identify core constructs within each theme.
目的:综合有关临床研究管理和质量保证所需的基础设施、能力和能力的已发表文献和国家法规。导言:世界卫生大会(WHA)第75.8(2022)号决议呼吁“加强协调和高质量临床试验的全球架构”。为此,必须了解和提高设计和提供高质量临床试验所需的基础设施、能力和能力。这项快速范围审查旨在确定法规、国家立法和已发表文献中有效管理临床试验的要求和建议的广度。调查结果将总结成主题。它将为开展观察性研究和介入性临床试验的单位的评估和发展提供框架。纳入标准:同行评议文献、灰色文献和推荐管理和质量保证临床试验所需的基础设施、能力和/或能力的国家立法。由设计、管理、资助、赞助、规范或监督临床试验的人员撰写的出版物。方法:通过Medline、Embase、PsycINFO和Global Health通过Ovid进行同行评议和灰色文献识别;斯高帕斯;Web of Science核心馆藏;以及使用特定字段代码的世界卫生组织全球索引Medicus,以增加搜索字符串的特异性。没有日期、语言或地理限制。重复的标题和摘要将由两名盲法审稿人筛选,差异由第三名审稿人解决。灰色文献可以通过同行评议的文献来识别,并辅以谷歌和DynaMed的结构化搜索。国家法规将从网上和现有摘要中获取。全文文献和法规将由单一审稿人筛选,并由第二审稿人按比例进行验证。数据将在NVivo软件中提取并编码为模式。所有项目和代码将使用主题框架分析进行总结,并确定每个主题中的核心结构。
Wellcome Open ResearchBiochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
5.50
自引率
0.00%
发文量
426
审稿时长
1 weeks
期刊介绍:
Wellcome Open Research publishes scholarly articles reporting any basic scientific, translational and clinical research that has been funded (or co-funded) by Wellcome. Each publication must have at least one author who has been, or still is, a recipient of a Wellcome grant. Articles must be original (not duplications). All research, including clinical trials, systematic reviews, software tools, method articles, and many others, is welcome and will be published irrespective of the perceived level of interest or novelty; confirmatory and negative results, as well as null studies are all suitable. See the full list of article types here. All articles are published using a fully transparent, author-driven model: the authors are solely responsible for the content of their article. Invited peer review takes place openly after publication, and the authors play a crucial role in ensuring that the article is peer-reviewed by independent experts in a timely manner. Articles that pass peer review will be indexed in PubMed and elsewhere. Wellcome Open Research is an Open Research platform: all articles are published open access; the publishing and peer-review processes are fully transparent; and authors are asked to include detailed descriptions of methods and to provide full and easy access to source data underlying the results to improve reproducibility.